Who are Tamsulosin Hydrochloride 0.4 milligrams's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dexmedetomidine Hydrochloride, Levadil, Wellbutrin, Hylorel, Methoxamin, MAPROTILINE.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tamsulosin-hydrochloride-0-4-milligrams.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Tamsulosin Hydrochloride 0.4 milligrams — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Tamsulosin Hydrochloride 0.4 milligrams (Tamsulosin Hydrochloride 0.4 milligrams) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1A adrenergic antagonist. Area: Urology.

marketed Alpha-1A adrenergic antagonist Alpha-1A adrenergic receptor Urology Small molecule Live · refreshed every 30 min

Target snapshot

Tamsulosin Hydrochloride 0.4 milligrams (Tamsulosin Hydrochloride 0.4 milligrams) — Pontificia Universidad Catolica de Chile. Tamsulosin selectively blocks alpha-1A adrenergic receptors in the prostate and bladder neck, relaxing smooth muscle to improve urine flow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Tamsulosin Hydrochloride 0.4 milligrams TARGET	Tamsulosin Hydrochloride 0.4 milligrams	Pontificia Universidad Catolica de Chile	marketed	Alpha-1A adrenergic antagonist	Alpha-1A adrenergic receptor
Dexmedetomidine Hydrochloride	dexmedetomidine-hydrochloride	Pfizer	marketed	dexmedetomidine	Alpha-1A adrenergic receptor	1999-01-01
Levadil	DILEVALOL		marketed	dilevalol	Alpha-1A adrenergic receptor, Alpha-1B adrenergic receptor, Beta-1 adrenergic receptor	1990-01-01
Wellbutrin	bupropion	GSK (GlaxoSmithKline)	marketed	NDRI (Norepinephrine-dopamine reuptake inhibitor)	Cytochrome P450 2C19, Neuronal acetylcholine receptor subunit alpha-7, Alpha-1A adrenergic receptor	1985-12-30
Hylorel	GUANADREL	Pfizer	marketed	guanadrel	Alpha-1A adrenergic receptor	1982-01-01
Methoxamin	METHOXAMINE	GSK	marketed	methoxamine	Alpha-1A adrenergic receptor	1982-01-01
MAPROTILINE	MAPROTILINE		marketed	maprotiline	Alpha-1A adrenergic receptor	1980-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2032-01-04 — Dexmedetomidine Hydrochloride · 8242158 · US
2032-01-04 — Dexmedetomidine Hydrochloride · 9616049 · US
2032-01-04 — Dexmedetomidine Hydrochloride · 8648106 · US
2032-01-04 — Dexmedetomidine Hydrochloride · 9320712 · US
2032-01-04 — Dexmedetomidine Hydrochloride · 8455527 · US
2032-01-04 — Dexmedetomidine Hydrochloride · 10016396 · US
2032-01-04 — Dexmedetomidine Hydrochloride · 8338470 · US
2032-07-04 — Dexmedetomidine Hydrochloride · 8242158*PED · US
2032-07-04 — Dexmedetomidine Hydrochloride · 8648106*PED · US
2032-07-04 — Dexmedetomidine Hydrochloride · 8455527*PED · US
2032-07-04 — Dexmedetomidine Hydrochloride · 8338470*PED · US
2032-07-04 — Dexmedetomidine Hydrochloride · 9320712*PED · US
2032-07-04 — Dexmedetomidine Hydrochloride · 9616049*PED · US
2036-04-20 — Dexmedetomidine Hydrochloride · 9717796 · US
2036-04-20 — Dexmedetomidine Hydrochloride · 9649296 · US
2039-06-26 — Dexmedetomidine Hydrochloride · 11517524 · US
2039-06-26 — Dexmedetomidine Hydrochloride · 11497711 · US
2039-06-26 — Dexmedetomidine Hydrochloride · 10792246 · US
2039-06-26 — Dexmedetomidine Hydrochloride · 11478422 · US

Sponsor landscape (Alpha-1A adrenergic antagonist class)

Pontificia Universidad Catolica de Chile · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Tamsulosin Hydrochloride 0.4 milligrams — Competitive Intelligence Brief. https://druglandscape.com/ci/tamsulosin-hydrochloride-0-4-milligrams. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab